Comparison of Clinical Characteristics of Patients With Rheumatoid Arthritis (RA) Identified By Physicians As Potentially Suitable For Biosimilar Infliximab Versus Those Who Were Not Considered Biosimilar Infliximab Suitable In Europe (EU)